Norwegian biotech Blue Helix Health is presenting at the international "NAD for Health: Opportunities and Challenges" conference (March 23–25), where researchers from Harvard, UC Berkeley and the Mayo Clinic are convening to examine both the promise and the limitations of NAD+ science in healthy ageing.
At the heart of the company's position is BluNADBooster, its flagship ingredient, which was evaluated in a randomised, double-blind, placebo-controlled clinical trial published in December 2025.
The study, involving 140 healthy ageing adults, found that BluNADBooster raised NAD+ levels by 26.48%—outperforming nicotinamide riboside (NR), which increased NAD+ levels by 22.69%.
The ingredient also reduced CD38 activity by nearly 18%, targeting one of the primary biological drivers of age-related NAD+ decline.
The trial reported functional outcomes beyond biochemistry alone, including improvements in mitochondrial efficiency, inflammatory markers (TNF-α, IL-6, GDF-15), cognitive performance and physical endurance.
"The market has been waiting for an NAD+ solution that goes beyond precursors alone," said Eric Anderson, Managing Director at NXT USA, Blue Helix's exclusive US distribution partner.
BluNADBooster represents a next-generation approach—one that strengthens the body's ability to generate and maintain healthy NAD+ levels while addressing the underlying mechanisms that cause NAD+ to decline with age.
Dr Mathias Ziegler, Professor of Biomedicine at the University of Bergen and Chief Science Officer of Blue Helix Health, is both presenting and moderating at the Copenhagen conference. His research focuses on mitochondrial NAD balance, a critical and contested area of ageing biology.
"We need to make more than our body's weight in NAD every day," said Ziegler. "Why? Because there are so
many processes driven by this molecule. We are trying to use this knowledge to actually help people live better."
For nutraceutical formulators and brand leaders, the message is clear: NAD+ supplementation involves more than just a single ingredient.
To address NAD+ decline effectively, a multi-pathway strategy is essential—one that integrates precursor support, CD38 inhibition and mitochondrial function.